journal
https://read.qxmd.com/read/32979984/neoadjuvant-chemotherapy-and-nivolumab-in-resectable-non-small-cell-lung-cancer-nadim-an-open-label-multicentre-single-arm-phase-2-trial
#1
Mariano Provencio, Ernest Nadal, Amelia Insa, María Rosario García-Campelo, Joaquín Casal-Rubio, Manuel Dómine, Margarita Majem, Delvys Rodríguez-Abreu, Alex Martínez-Martí, Javier De Castro Carpeño, Manuel Cobo, Guillermo López Vivanco, Edel Del Barco, Reyes Bernabé Caro, Nuria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Eva Pereira, Ana Royuela, Marta Casarrubios, Clara Salas Antón, Edwin R Parra, Ignacio Wistuba, Virginia Calvo, Raquel Laza-Briviesca, Atocha Romero, Bartomeu Massuti, Alberto Cruz-Bermúdez
BACKGROUND: Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally advanced stage disease. We aimed to assess the antitumour activity and safety of neoadjuvant chemoimmunotherapy for resectable stage IIIA NSCLC. METHODS: This was an open-label, multicentre, single-arm phase 2 trial done at 18 hospitals in Spain. Eligible patients were aged 18 years or older with histologically or cytologically documented treatment-naive American Joint Committee on Cancer-defined stage IIIA NSCLC that was deemed locally to be surgically resectable by a multidisciplinary clinical team, and an Eastern Cooperative Oncology Group performance status of 0 or 1...
September 24, 2020: Lancet Oncology
https://read.qxmd.com/read/32979983/esmo-virtual-congress-2020
#2
Katherine Gourd, Cheryl Lai, Cheryl Reeves
No abstract text is available yet for this article.
September 24, 2020: Lancet Oncology
https://read.qxmd.com/read/32979982/burnout-among-cancer-professionals-during-covid-19
#3
Talha Khan Burki
No abstract text is available yet for this article.
September 24, 2020: Lancet Oncology
https://read.qxmd.com/read/32971005/durvalumab-alone-and-durvalumab-plus-tremelimumab-versus-chemotherapy-in-previously-untreated-patients-with-unresectable-locally-advanced-or-metastatic-urothelial-carcinoma-danube-a-randomised-open-label-multicentre-phase-3-trial
#4
Thomas Powles, Michiel S van der Heijden, Daniel Castellano, Matthew D Galsky, Yohann Loriot, Daniel P Petrylak, Osamu Ogawa, Se Hoon Park, Jae-Lyun Lee, Ugo De Giorgi, Martin Bögemann, Aristotelis Bamias, Bernhard J Eigl, Howard Gurney, Som D Mukherjee, Yves Fradet, Iwona Skoneczna, Marinos Tsiatas, Andrey Novikov, Cristina Suárez, André P Fay, Ignacio Duran, Andrea Necchi, Sophie Wildsmith, Philip He, Natasha Angra, Ashok K Gupta, Wendy Levin, Joaquim Bellmunt
BACKGROUND: Survival outcomes are poor for patients with metastatic urothelial carcinoma who receive standard, first-line, platinum-based chemotherapy. We assessed the overall survival of patients who received durvalumab (a PD-L1 inhibitor), with or without tremelimumab (a CTLA-4 inhibitor), as a first-line treatment for metastatic urothelial carcinoma. METHODS: DANUBE is an open-label, randomised, controlled, phase 3 trial in patients with untreated, unresectable, locally advanced or metastatic urothelial carcinoma, conducted at 224 academic research centres, hospitals, and oncology clinics in 23 countries...
September 21, 2020: Lancet Oncology
https://read.qxmd.com/read/32966811/surufatinib-in-advanced-extrapancreatic-neuroendocrine-tumours-sanet-ep-a-randomised-double-blind-placebo-controlled-phase-3-study
#5
Jianming Xu, Lin Shen, Zhiwei Zhou, Jie Li, Chunmei Bai, Yihebali Chi, Zhiping Li, Nong Xu, Enxiao Li, Tianshu Liu, Yuxian Bai, Ying Yuan, Xingya Li, Xiuwen Wang, Jia Chen, Jieer Ying, Xianjun Yu, Shukui Qin, Xianglin Yuan, Tao Zhang, Yanhong Deng, Dianrong Xiu, Ying Cheng, Min Tao, Ru Jia, Wei Wang, Jing Li, Songhua Fan, Mengye Peng, Weiguo Su
BACKGROUND: Therapeutic options for advanced neuroendocrine tumours (NETs) are limited. We investigated the efficacy and safety of surufatinib (HMPL-012, sulfatinib) in patients with extrapancreatic NETs. METHODS: SANET-ep was a randomised, double-blind, placebo-controlled, phase 3 trial undertaken at 24 hospitals across China. Patients (aged 18 years or older) with unresectable or metastatic, well differentiated, extrapancreatic NETs, with an Eastern Cooperative Oncology Group performance status of 0 or 1, and progression on no more than two types of previous systemic regimens were enrolled...
September 18, 2020: Lancet Oncology
https://read.qxmd.com/read/32966810/surufatinib-in-advanced-pancreatic-neuroendocrine-tumours-sanet-p-a-randomised-double-blind-placebo-controlled-phase-3-study
#6
Jianming Xu, Lin Shen, Chunmei Bai, Wei Wang, Jie Li, Xianjun Yu, Zhiping Li, Enxiao Li, Xianglin Yuan, Yihebali Chi, Yongmei Yin, Wenhui Lou, Nong Xu, Yuxian Bai, Tao Zhang, Dianrong Xiu, Xiuwen Wang, Ying Yuan, Jia Chen, Shukui Qin, Ru Jia, Ming Lu, Yuejuan Cheng, Zhiwei Zhou, Jing Li, James He, Weiguo Su
BACKGROUND: Surufatinib showed superior efficacy in extrapancreatic neuroendocrine tumours (NETs) in the phase 3 SANET-ep study. In SANET-p, we aimed to assess the efficacy and safety of surufatinib in patients with advanced pancreatic NETs. METHODS: SANET-p was a multicentre, randomised, double-blind, placebo-controlled, phase 3 study, done in 21 hospitals across China. Eligible patients were adults (aged 18 years or older) with progressive, advanced, well differentiated pancreatic NETs, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and progression on up to two kinds of previous systemic regimens for advanced disease...
September 18, 2020: Lancet Oncology
https://read.qxmd.com/read/32961120/the-current-state-of-adjuvant-therapy-of-melanoma
#7
Ahmad A Tarhini
No abstract text is available yet for this article.
September 18, 2020: Lancet Oncology
https://read.qxmd.com/read/32961119/adjuvant-nivolumab-versus-ipilimumab-in-resected-stage-iiib-c-and-stage-iv-melanoma-checkmate-238-4-year-results-from-a-multicentre-double-blind-randomised-controlled-phase-3-trial
#8
Paolo A Ascierto, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M Arance, Stephane Dalle, C Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni, Iván Márquez-Rodas, Marcus O Butler, Michele Maio, Mark R Middleton, Luis de la Cruz-Merino, Petr Arenberger, Victoria Atkinson, Andrew Hill, Leslie A Fecher, Michael Millward, Nikhil I Khushalani, Paola Queirolo, Maurice Lobo, Veerle de Pril, John Loffredo, James Larkin, Jeffrey Weber
BACKGROUND: Previously, findings from CheckMate 238, a double-blind, phase 3 adjuvant trial in patients with resected stage IIIB-C or stage IV melanoma, showed significant improvements in recurrence-free survival and distant metastasis-free survival with nivolumab versus ipilimumab. This report provides updated 4-year efficacy, initial overall survival, and late-emergent safety results. METHODS: This multicentre, double-blind, randomised, controlled, phase 3 trial was done in 130 academic centres, community hospitals, and cancer centres across 25 countries...
September 18, 2020: Lancet Oncology
https://read.qxmd.com/read/32941794/preoperative-radiotherapy-plus-surgery-versus-surgery-alone-for-patients-with-primary-retroperitoneal-sarcoma-eortc-62092-strass-a-multicentre-open-label-randomised-phase-3-trial
#9
Sylvie Bonvalot, Alessandro Gronchi, Cécile Le Péchoux, Carol J Swallow, Dirk Strauss, Pierre Meeus, Frits van Coevorden, Stephan Stoldt, Eberhard Stoeckle, Piotr Rutkowski, Marco Rastrelli, Chandrajit P Raut, Daphne Hompes, Antonino De Paoli, Claudia Sangalli, Charles Honoré, Peter Chung, Aisha Miah, Jean Yves Blay, Marco Fiore, Jean-Jacques Stelmes, Angelo P Dei Tos, Elizabeth H Baldini, Saskia Litière, Sandrine Marreaud, Hans Gelderblom, Rick L Haas
BACKGROUND: Unlike for extremity sarcomas, the efficacy of radiotherapy for retroperitoneal sarcoma is not established. The aim of this study was to evaluate the impact of preoperative radiotherapy plus surgery versus surgery alone on abdominal recurrence-free survival. METHODS: EORTC-62092 is an open-label, randomised, phase 3 study done in 31 research institutions, hospitals, and cancer centres in 13 countries in Europe and North America. Adults (aged ≥18 years) with histologically documented, localised, primary retroperitoneal sarcoma that was operable and suitable for radiotherapy, who had not been previously treated and had a WHO performance status and American Society of Anesthesiologists score of 2 or lower, were centrally randomly assigned (1:1), using an interactive web response system and a minimisation algorithm, to receive either surgery alone or preoperative radiotherapy followed by surgery...
September 14, 2020: Lancet Oncology
https://read.qxmd.com/read/32941793/the-strass-trial-an-important-step-in-the-right-direction
#10
Kenneth Cardona
No abstract text is available yet for this article.
September 14, 2020: Lancet Oncology
https://read.qxmd.com/read/32926841/quality-of-life-in-patients-with-metastatic-prostate-cancer-following-treatment-with-cabazitaxel-versus-abiraterone-or-enzalutamide-card-an-analysis-of-a-randomised-multicentre-open-label-phase-4-study
#11
Karim Fizazi, Gero Kramer, Jean-Christophe Eymard, Cora N Sternberg, Johann de Bono, Daniel Castellano, Bertrand Tombal, Christian Wülfing, Michael Liontos, Joan Carles, Roberto Iacovelli, Bohuslav Melichar, Ásgerður Sverrisdóttir, Christine Theodore, Susan Feyerabend, Carole Helissey, Stéphane Oudard, Gaetano Facchini, Elizabeth M Poole, Ayse Ozatilgan, Christine Geffriaud-Ricouard, Samira Bensfia, Ronald de Wit
BACKGROUND: In the CARD study, cabazitaxel significantly improved radiographic progression-free survival and overall survival versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and the alternative androgen signalling-targeted inhibitor. Here, we report the quality-of-life outcomes from the CARD study. METHODS: CARD was a randomised, multicentre, open-label, phase 4 study involving 62 clinical sites across 13 European countries...
September 11, 2020: Lancet Oncology
https://read.qxmd.com/read/32919529/tumour-mutational-burden-as-a-driver-for-treatment-choice-in-resistant-tumours-and-beyond
#12
Melissa Bersanelli
No abstract text is available yet for this article.
September 10, 2020: Lancet Oncology
https://read.qxmd.com/read/32919528/less-survivable-cancers-taskforce-calls-for-faster-diagnosis
#13
Talha Khan Burki
No abstract text is available yet for this article.
September 10, 2020: Lancet Oncology
https://read.qxmd.com/read/32919527/circulating-tumour-dna-analysis-to-direct-therapy-in-advanced-breast-cancer-plasmamatch-a-multicentre-multicohort-phase-2a-platform-trial
#14
Nicholas C Turner, Belinda Kingston, Lucy S Kilburn, Sarah Kernaghan, Andrew M Wardley, Iain R Macpherson, Richard D Baird, Rebecca Roylance, Peter Stephens, Olga Oikonomidou, Jeremy P Braybrooke, Mark Tuthill, Jacinta Abraham, Matthew C Winter, Hannah Bye, Michael Hubank, Heidrun Gevensleben, Ros Cutts, Claire Snowdon, Daniel Rea, David Cameron, Abeer Shaaban, Katrina Randle, Sue Martin, Katie Wilkinson, Laura Moretti, Judith M Bliss, Alistair Ring
BACKGROUND: Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the accuracy of ctDNA testing in advanced breast cancer and the ability of ctDNA testing to select patients for mutation-directed therapy. METHODS: We did an open-label, multicohort, phase 2a, platform trial of ctDNA testing in 18 UK hospitals. Participants were women (aged ≥18 years) with histologically confirmed advanced breast cancer and an Eastern Cooperative Oncology Group performance status 0-2...
September 10, 2020: Lancet Oncology
https://read.qxmd.com/read/32919526/association-of-tumour-mutational-burden-with-outcomes-in-patients-with-advanced-solid-tumours-treated-with-pembrolizumab-prospective-biomarker-analysis-of-the-multicohort-open-label-phase-2-keynote-158-study
#15
Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L Kindler, Jose A Lopez-Martin, Wilson H Miller, Antoine Italiano, Steven Kao, Sarina A Piha-Paul, Jean-Pierre Delord, Robert R McWilliams, David A Fabrizio, Deepti Aurora-Garg, Lei Xu, Fan Jin, Kevin Norwood, Yung-Jue Bang
BACKGROUND: Tumour mutational burden (TMB) has been retrospectively correlated with response to immune checkpoint blockade. We prospectively explored the association of high tissue TMB (tTMB-high) with outcomes in ten tumour-type-specific cohorts from the phase 2 KEYNOTE-158 study, which assessed the anti-PD-1 monoclonal antibody pembrolizumab in patients with selected, previously treated, advanced solid tumours. METHODS: In the multi-cohort, open-label, non-randomised, phase 2 KEYNOTE-158 study, patients were enrolled from 81 academic facilities and community-based institutions across 21 countries in Africa, the Americas, Asia, and Europe...
September 10, 2020: Lancet Oncology
https://read.qxmd.com/read/32916092/2020-us-election-and-implications-for-cancer-care
#16
Mary Beth Nierengarten
No abstract text is available yet for this article.
September 8, 2020: Lancet Oncology
https://read.qxmd.com/read/32891190/correction-to-lancet-oncol-2020-published-online-aug-24-https-doi-org-10-1016-s1470-2045-20-30442-3
#17
(no author information available yet)
No abstract text is available yet for this article.
September 3, 2020: Lancet Oncology
https://read.qxmd.com/read/32866432/carfilzomib-or-bortezomib-in-combination-with-lenalidomide-and-dexamethasone-for-patients-with-newly-diagnosed-multiple-myeloma-without-intention-for-immediate-autologous-stem-cell-transplantation-endurance-a-multicentre-open-label-phase-3-randomised-controlled
#18
Shaji K Kumar, Susanna J Jacobus, Adam D Cohen, Matthias Weiss, Natalie Callander, Avina K Singh, Terri L Parker, Alexander Menter, Xuezhong Yang, Benjamin Parsons, Pankaj Kumar, Prashant Kapoor, Aaron Rosenberg, Jeffrey A Zonder, Edward Faber, Sagar Lonial, Kenneth C Anderson, Paul G Richardson, Robert Z Orlowski, Lynne I Wagner, S Vincent Rajkumar
BACKGROUND: Bortezomib, lenalidomide, and dexamethasone (VRd) is a standard therapy for newly diagnosed multiple myeloma. Carfilzomib, a next-generation proteasome inhibitor, in combination with lenalidomide and dexamethasone (KRd), has shown promising efficacy in phase 2 trials and might improve outcomes compared with VRd. We aimed to assess whether the KRd regimen is superior to the VRd regimen in the treatment of newly diagnosed multiple myeloma in patients who were not being considered for immediate autologous stem-cell transplantation (ASCT)...
August 28, 2020: Lancet Oncology
https://read.qxmd.com/read/32861274/brocade3-a-challenge-to-the-treatment-paradigm-in-brca-breast-cancer
#19
Melinda L Telli
No abstract text is available yet for this article.
August 27, 2020: Lancet Oncology
https://read.qxmd.com/read/32861273/veliparib-with-carboplatin-and-paclitaxel-in-brca-mutated-advanced-breast-cancer-brocade3-a-randomised-double-blind-placebo-controlled-phase-3-trial
#20
Véronique Diéras, Hyo S Han, Bella Kaufman, Hans Wildiers, Michael Friedlander, Jean-Pierre Ayoub, Shannon L Puhalla, Igor Bondarenko, Mario Campone, Erik H Jakobsen, Mathilde Jalving, Cristina Oprean, Marketa Palácová, Yeon Hee Park, Yaroslav Shparyk, Eduardo Yañez, Nikhil Khandelwal, Madan G Kundu, Matthew Dudley, Christine K Ratajczak, David Maag, Banu K Arun
BACKGROUND: BRCA1 or BRCA2-mutated breast cancers are sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors and platinum agents owing to deficiency in homologous recombination repair of DNA damage. In this trial, we compared veliparib versus placebo in combination with carboplatin and paclitaxel, and continued as monotherapy if carboplatin and paclitaxel were discontinued before progression, in patients with HER2-negative advanced breast cancer and a germline BRCA1 or BRCA2 mutation...
August 27, 2020: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"